ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

• Montalban X Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.
• Gold R Department of Neurology, Ruhr University, St. Josef-Hospital, Bochum, Germany.
• Thompson AJ Department of Brain Repair & Rehabilitation and Faculty of Brain Sciences, University College London Institute of Neurology, London, UK.
• Otero-Romero S Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain/Preventive Medicine and Epidemiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
• Amato MP Department of Neurosciences, Psychology, Drugs and Child Health Area (NEUROFARBA), Section Neurosciences, University of Florence, Florence, Italy.
• Chandraratna D Multiple Sclerosis International Federation, London, UK.
• Clanet M Department of Neurology, Toulouse University Hospital, Toulouse, France.
• Comi G Neurological Department, Institute of Experimental Neurology (INSPE), Scientific Institute Hospital San Raffaele, Universita' Vita-Salute San Raffaele, Milan, Italy.
• Derfuss T Departments of Neurology and Biomedicine, University Hospital Basel, Basel, Switzerland.
• Fazekas F Department of Neurology, Medical University of Graz, Graz, Austria.
• Hartung HP Multiple Sclerosis Center, Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
• Havrdova E Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
• Hemmer B Department of Neurology, Klinikum Rechts der Isar, Technische Universität München and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
• Kappos L University Hospital Basel, Basel, Switzerland.
• Liblau R INSERM UMR U1043 - CNRS U5282, Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.
• Lubetzki C Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1127, ICM-GHU Pitié-Salpêtrière, Paris, France.
• Marcus E Centre for Outcomes Research and Effectiveness (CORE), Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
• Miller DH NMR Research Unit and Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, UK.
• Olsson T Neuroimmunology Unit, Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden.
• Pilling S Centre for Outcomes Research and Effectiveness (CORE), Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
• Selmaj K Department of Neurology, Medical University of Lodz, Lodz, Poland.
• Siva A Clinical Neuroimmunology Unit and MS Clinic, Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
• Sorensen PS Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet, Denmark.
• Sormani MP Biostatistics Unit, University of Genoa, Genoa, Italy.
• Thalheim C European Multiple Sclerosis Platform (EMSP), Schaerbeek, Belgium.
• Wiendl H Department of Neurology, University of Münster, Münster, Germany.
• Zipp F Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Show more…

GRADE methodology

Multiple sclerosis

disease-modifying therapies

guideline

Consensus

Evidence-Based Medicine

Humans

Immunologic Factors

Immunomodulation

Multiple Sclerosis

Practice Guidelines as Topic